Understanding Reglan Tardive Dyskinesia: Testing and Evaluation

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

What is the statute of limitations for Reglan tardive dyskinesia claims in Washington

In Washington, the statute of limitations for Reglan-related tardive dyskinesia claims typically begins when the injury is discovered or should have been discovered. This time limit varies, so it is crucial to consult a qualified attorney promptly to ensure your claim is filed within the applicable deadline.

From General Health Awareness to Targeted Risk Assessment

If you or a loved one has taken Reglan and developed involuntary muscle movements, you may be concerned about tardive dyskinesia. This condition, linked to long-term use of metoclopramide, requires careful evaluation and testing. Building on decades of medical understanding of drug-induced movement disorders, this page covers the diagnostic tools and assessments used to identify tardive dyskinesia.

Understanding Reglan and Tardive Dyskinesia

Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults who fail conventional therapy, and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA-approved labeling includes a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). TD is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities, and may be disfiguring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling instructs that Reglan should be used for the shortest duration necessary, and the need for continued treatment should be periodically reassessed (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, total treatment duration should not exceed 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan tablets are not recommended for use in pediatric patients due to the risk of developing TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Mechanism and Clinical Presentation of Tardive Dyskinesia

The mechanistic pathway linking Reglan to TD involves metoclopramide's dopamine D2 receptor antagonism in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent involuntary movements. The labeling notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Clinical presentation of TD typically includes orofacial movements such as lip smacking, chewing, or tongue protrusion, but can also involve choreiform movements of the limbs or trunk. Diagnosis is based on clinical examination and history of exposure to a dopamine-blocking agent like metoclopramide. The condition can be irreversible even after discontinuation of the drug. From a risk perspective, the adequacy of warnings regarding Reglan and TD is a central concern. The boxed warning is prominently placed in the prescribing information, but patients may not have been adequately informed about the risk, especially when Reglan is used off-label or for longer durations than recommended. The labeling explicitly states that Reglan should be used for the shortest duration and that the maximum treatment period for gastroesophageal reflux is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, in practice, some patients have been prescribed Reglan for months or years, increasing cumulative exposure and TD risk. The warning also advises immediate discontinuation if signs or symptoms of TD develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Failure to monitor or discontinue in a timely manner may contribute to harm.

Statute of Limitations for Reglan Claims in Washington

For affected patients in Washington, attorney-related considerations include the statute of limitations for filing a claim. In Washington, the statute of limitations for personal injury claims, including those related to prescription drug injuries, is generally three years from the date the injury was discovered or reasonably should have been discovered. For TD, the timeline between exposure and documented harm can be variable. TD may develop after weeks, months, or years of metoclopramide use, and symptoms may be subtle initially. The labeling notes that risk increases with duration and cumulative dose (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients may not immediately associate their movement disorder with Reglan use, especially if the drug was taken in the past. The discovery rule in Washington may allow the statute of limitations to begin when the patient knew or should have known that TD was caused by Reglan. Legal counsel can help determine the applicable deadline based on individual circumstances. Evidence of harm includes documented cases where patients developed TD after Reglan use, with the FDA labeling acknowledging the risk. The boxed warning states that TD can be serious and potentially irreversible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For attorney-related considerations, it is important to gather medical records documenting Reglan prescription, duration of use, and onset of TD symptoms. Expert testimony may be needed to establish causation and the adequacy of warnings provided by the prescribing physician or manufacturer. The labeling's contraindication for patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397) underscores the need for careful patient screening.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-induced tardive dyskinesia claims in Washington?

In Washington, the statute of limitations for personal injury claims, including those related to prescription drug injuries like tardive dyskinesia from Reglan, is generally three years from the date the injury was discovered or reasonably should have been discovered. The discovery rule may apply, meaning the clock starts when the patient knew or should have known that TD was caused by Reglan. It is important to consult an attorney to determine the specific deadline based on individual circumstances.

What evidence is needed to support a Reglan tardive dyskinesia claim?

To support a claim, you should gather medical records documenting the Reglan prescription, duration of use, and onset of TD symptoms. Expert testimony may be needed to establish causation and the adequacy of warnings. The FDA labeling acknowledges the risk of TD with Reglan use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397), which can serve as evidence of the known risk.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.